Effects of SGLT2 (Sodium-Dependent Type 2 Glucose Transporters) on Different Systems

Main Article Content

Miguel Ángel Sánchez Dorantes
María Erika Boza Medrano
Fernanda Guijosa Ortega
Omar Alejandro Avila Hernández
Manuel Enrique Vadillo Flores
Leonardo Bryant Sánchez Franco

Abstract

SGLT2 inhibitors are a class of drugs commonly used in the treatment of type 2 diabetes. Although these drugs are effective in controlling blood sugar, they also have significant systemic side effects that must be considered. The most common side effects of SGLT2 inhibitors include urinary tract infections, euglycemic ketoacidosis, orthostatic hypotension, dehydration, and cardiovascular adverse events. In addition, an increased incidence of bone fractures and decreased bone mineral density has been observed in patients taking these drugs.


It is important that physicians consider these side effects when prescribing SGLT2 inhibitors and monitor patients regularly for any complications. Individual benefit-risk assessment is critical before deciding to prescribe these drugs. In summary, although SGLT2 inhibitors are an effective treatment option for type 2 diabetes, their use should be carefully evaluated and monitored to minimize systemic side effects.

Article Details

How to Cite
Miguel Ángel Sánchez Dorantes, María Erika Boza Medrano, Fernanda Guijosa Ortega, Omar Alejandro Avila Hernández, Manuel Enrique Vadillo Flores, & Leonardo Bryant Sánchez Franco. (2023). Effects of SGLT2 (Sodium-Dependent Type 2 Glucose Transporters) on Different Systems . International Journal of Medical Science and Clinical Research Studies, 3(05), 826–828. https://doi.org/10.47191/ijmscrs/v3-i5-07
Section
Articles

References

I. Rosenstock, J. et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care, 2012; 35: 1473-1478.

II. European Medicines Agency (EMA). Sodium-glucose co-transporter 2 (SGLT2) inhibitors: PRAC recommends use restrictions because of rare occurrences of a serious condition of the blood (ketoacidosis). 2015.

III. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). 2016.

IV. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med, 2020; 383: 1413-1424.

V. U.S. National Library of Medicine. Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors): drug safety communication - concerning rare but serious infections of the genitals and area around the genitals. 2018.

VI. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18) 32590-X. PMID: 30424892.

VII. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018 Jul;61(7):2108-2117. doi: 10.1007/s00125-018-4630-2. Epub 2018 May 10. PMID: 29748881.

VIII. Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018 May 23;361:k2231. doi: 10.1136/bmj.k2231. PMID: 29792389.

IX. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. U.S. Food and Drug Administration. 2015 May https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-sglt2-inhibitors-diabetes-may-result-serious-condition-too.

X. Goldenberg RM, Berard LD, Cheng AYY, et al. SGLT2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. Clin Ther. 2016 Dec;38(12):2654-2664.e1. doi: 10.1016/j.clinthera.2016.11.002. Epub 2016 Nov 22. PMID: 27889318.

XI. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015 Aug;38(8):1687-93. doi: 10.2337/dc15-0843. Epub 2015 Jun 12. PMID: 26068503.

XII. Bailey CJ, Day C. SGLT2 inhibitors: glucotoxicity, lipotoxicity and beyond. Diabetologia. 2016 Mar;59(3):467-78. doi: 10.1007/s00125-015-3844-9. Epub 2015 Dec 12. PMID: 26662530.

XIII. Kohan, D. E., Fioretto, P., & Tang, W. (2019). Long-term kidney outcomes among users of sodium-glucose cotransporter 2 inhibitors in real-world clinical practice (PROTECT-2): A cohort study. The Lancet Diabetes & Endocrinology, 7(5), 404-411. doi: 10.1016/S2213-8587(19)30055-1.

XIV. Watts, N. B., Bilezikian, J. P., Usiskin, K., Edwards, R., Desai, M., Law, G., ... & Meininger, G. (2016). Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism, 101(1), 157-166. doi: 10.1210/jc.2015-2691.

XV. O'Brien, M. J., Karam, S. L., Wallia, A., Kang, R. H., Cooper, A. J., & Huang, E. S. (2018). Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes. JAMA Network Open, 1(8), e186125-e186125.

doi: 10.1001/jamanetworkopen.2018.6125.

Most read articles by the same author(s)